$16.08
8.14% yesterday
Nasdaq, Nov 15, 09:50 pm CET
ISIN
US1523091007
Symbol
CNTA
Sector
Industry

Centessa Pharmaceuticals plc - ADR Stock price

$16.00
-0.09 0.56% 1M
+7.21 82.03% 6M
+8.04 101.01% YTD
+8.79 121.91% 1Y
+4.08 34.23% 3Y
-5.75 26.44% 5Y
-5.75 26.44% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-1.50 8.57%
ISIN
US1523091007
Symbol
CNTA
Sector
Industry

Key metrics

Market capitalization $2.11b
Enterprise Value $1.67b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 242.09
P/S ratio (TTM) P/S ratio 304.85
P/B ratio (TTM) P/B ratio 4.22
Revenue (TTM) Revenue $6.91m
EBIT (operating result TTM) EBIT $-162.46m
Free Cash Flow (TTM) Free Cash Flow $-130.86m
Cash position $518.45m
EPS (TTM) EPS $-1.53
P/E forward negative
Short interest 2.06%
Show more

Is Centessa Pharmaceuticals plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Centessa Pharmaceuticals plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

Buy
100%

Financial data from Centessa Pharmaceuticals plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
6.91 6.91
-
100%
- Direct Costs 0.96 0.96
60% 60%
14%
5.95 5.95
1,092% 1,092%
86%
- Selling and Administrative Expenses 48 48
12% 12%
691%
- Research and Development Expense 120 120
3% 3%
1,733%
-162 -162
9% 9%
-2,337%
- Depreciation and Amortization 0.96 0.96
60% 60%
14%
EBIT (Operating Income) EBIT -162 -162
9% 9%
-2,351%
Net Profit -162 -162
3% 3%
-2,345%

In millions USD.

Don't miss a Thing! We will send you all news about Centessa Pharmaceuticals plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Centessa Pharmaceuticals plc - ADR Stock News

Neutral
GlobeNewsWire
4 days ago
BOSTON and LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Positive
MarketBeat
about 2 months ago
Centessa Pharmaceuticals NASDAQ: CNTA is a biotechnology stock that has nearly doubled its value so far this year, and its run may not be over. Analysts at Morgan Stanley have just massively raised their price target for the company.
Neutral
GlobeNewsWire
about 2 months ago
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders
More Centessa Pharmaceuticals plc - ADR News

Company Profile

Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company was founded on October 26, 2020 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Saurabh Saha
Employees 76
Founded 2013
Website centessa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today